SPX 104
Alternative Names: SPX-104Latest Information Update: 15 Sep 2023
Price :
$50 *
At a glance
- Originator Sparx Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action LILRB2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Sep 2023 SPX 104 is available for licensing as of 08 Sep 2023. https://sparxbio.com/?page_id=3238 (Sparx Therapeutics pipeline, September 2023)
- 18 Apr 2023 Preclinical trials in Cancer in USA (Parenteral) before September 2023 (Sparx Therapeutics pipeline, April 2023)
- 18 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)